Key terms
About THTX
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest THTX news
Apr 15
9:06pm ET
Theratechnologies Announces Virtual Annual Meeting
Apr 08
4:36pm ET
Theratechnologies announces data presentation of SORT1+ technology at AACR
Apr 05
1:27pm ET
Theratechnologies Welcomes Elina Tea to Board
Apr 05
11:37am ET
Theratechnologies Strengthens Board with New Appointment
Apr 05
11:04am ET
Theratechnologies appoints Elina Tea to board of directors
Mar 22
5:27pm ET
Theratechnologies Refocuses on Pioneering Ovarian Cancer Trial
Mar 22
2:57pm ET
Theratechnologies Welcomes New Board Member
Mar 22
10:07am ET
Theratechnologies Refocuses on Commercial Growth
Mar 22
9:39am ET
Theratechnologies to phase down preclinical oncology research activities
Mar 21
9:07pm ET
Theratechnologies Bolsters Board with New Director
Mar 21
1:27pm ET
Theratechnologies Escalates Ovarian Cancer Trial Dose
Mar 21
8:07am ET
Theratechnologies Trials Novel Ovarian Cancer Treatment
Mar 21
7:38am ET
Theratechnologies starts increased dose level in Phase 1 trial of sudocetaxel
Feb 29
1:20pm ET
Analysts Offer Insights on Healthcare Companies: Theratechnologies (THTX), MoonLake Immunotherapeutics (MLTX) and DENTSPLY SIRONA (XRAY)
Feb 27
8:08am ET
Theratechnologies Faces FDA Setback on Trogarzo
Feb 27
7:32am ET
Theratechnologies announces FDA RTF regarding sBLA for Trogarzo
Feb 22
7:53am ET
Theratechnologies price target lowered to $5 from $8 at Canaccord
Feb 21
7:33am ET
Theratechnologies reports Q4 revenue $23.45M, consensus $23.36M
Feb 20
7:41am ET
Theratechnologies announces publication in Frontiers in Immunology on TH1902
Feb 15
7:35am ET
Theratechnologies completes enrollment of first six patients in Phase 1 trial
Jan 24
7:01am ET
Theratechnologies receives CRL from FDA for 58 formulation of tesamorelin sBLA
Jan 23
7:33am ET
Theratechnologies says FDA continuing to review sBLA for tesamorelin F8
THTX Financials
Key terms
Ad Feedback
THTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
THTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range